<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635125</url>
  </required_header>
  <id_info>
    <org_study_id>BYS-MD-48</org_study_id>
    <nct_id>NCT03635125</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine</brief_title>
  <official_title>A Prospective, Randomized, Open-Label, Active-Comparator, Blinded-Endpoint, 12-week Forced-Titration Study of the Efficacy and Safety of Nebivolol Verses Metoprolol in Hypertensive Subjects Taking Amlodipine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trinity Hypertension &amp; Metabolic Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trinity Hypertension &amp; Metabolic Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study is to evaluate the effect of Nebivolol to treat high blood pressure compared to an
      already approved drug, Metoprolol ER with background treatment of Amlodipine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, single center study consisting of a 2 to 4 week baseline washout phase, a 12-week
      Amlodipine background treatment phase followed by a 4-week Low Dose Nebivolol/Metoprolol
      Treatment phase and a 4-week High Dose Nebivolol/Metoprolol Treatment Phase.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2010</start_date>
  <completion_date type="Actual">July 18, 2011</completion_date>
  <primary_completion_date type="Actual">May 26, 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>12-week Amlodipine background treatment phase followed by a 4-week Low dose Nebivolol/Metoprolol treatment phase and a 4-week high dose Nebivolol/Metoprolol treatment phase</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change from baseline in trough Diastolic Blood Pressure</measure>
    <time_frame>4 and 8 weeks of treatment</time_frame>
    <description>Mean change by millimeters of mercury from baseline in trough Diastolic Blood Pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Edema Measurement</measure>
    <time_frame>4 and 8 weeks of treatment</time_frame>
    <description>Mean change in edema measurement by water immersion of treatment in millimeters of water</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in trough Systolic blood pressure of treatment.</measure>
    <time_frame>4 and 8 weeks of treatment</time_frame>
    <description>Change from baseline by millimeters of mercury in trough Systolic blood pressure of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving Blood pressure goals</measure>
    <time_frame>4 and 8 weeks of treatment</time_frame>
    <description>Percentage of subjects achieving Blood pressure goals of either Nebivolol compared to Metoprolol</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>JNC 7 Stage 1 or 2 Hypertension</condition>
  <arm_group>
    <arm_group_label>Background treatment phase</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>A 12- week Amlodipine 10 mg background treatment phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Treatment Phase-Nebivolol I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4-week low dose Nebivolol10 mg/Metoprolol 50 mg treatment phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose treatment Phase-Nebivolol II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4-week High dose Nebivolol 20 mg/Metoprolol 100mg treatment phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baseline Washout Phase</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2 to 4 week Baseline Washout Phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol I</intervention_name>
    <description>Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20 mg or Metoprolol 100mg</description>
    <arm_group_label>High dose treatment Phase-Nebivolol II</arm_group_label>
    <arm_group_label>Low Dose Treatment Phase-Nebivolol I</arm_group_label>
    <other_name>Metoprolol I</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol II</intervention_name>
    <description>Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20mg or Metoprolol 100mg</description>
    <arm_group_label>High dose treatment Phase-Nebivolol II</arm_group_label>
    <arm_group_label>Low Dose Treatment Phase-Nebivolol I</arm_group_label>
    <other_name>Metoprolol II</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Baseline Washout Phase</intervention_name>
    <description>2 to 4 week Baseline Washout Phase</description>
    <arm_group_label>Baseline Washout Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of reading, comprehending the consent process and providing written informed
             consent to participate in the study.

          -  Male or female equal/over 18 years of age.

          -  Stage I-II hypertension defined as a baseline mean seated cuff Diastolic blood
             pressure of equal/over 95 mmHg and equal/less 115 mmHg and Systolic blood pressure
             equal/less to 180 mmHg at two consecutive qualifying visits during the placebo run in
             period.

          -  Arm circumference less 45 cm

          -  Compliance with single blind placebo capsules between V1-4 of 80-120%.

          -  Women may be enrolled if all three of the following criteria are met:

          -  Have a negative serum pregnancy test at screening

          -  Are not breastfeeding

          -  Do not plan to become pregnant during the study and if one of the three criteria is
             met:

          -  Have had a hysterectomy or tubal ligation at least 6 months prior to signing the
             informed consent form

          -  Have been postmenopausal for at least 1 year

          -  Are of childbearing potential and will practice one the following methods of birth
             control throughout the study: oral, patch, injectable, or implantable hormone
             contraception, intrauterine device, diaphragm plus spermicide or female condom plus
             spermicide. Abstinence, partner's vasectomy are not acceptable methods of
             contraception.

        Exclusion Criteria:

          -  Known allergy or hypersensitivity to Beta Blockers.

          -  Known allergy or hypersensitivity to Calcium Channel Blockers.

          -  Patients with severe hypertension (mean seated cuff Diastolic blood pressure &gt; 115
             mmHg or mean seated Systolic blood pressure &gt;180 mmHg) or any form of secondary
             hypertension.

          -  Patients within the past 6 months with a history of hypertensive encephalopathy,
             stroke or transient ischemic attack.

          -  Patients within the last 6 months with a history of myocardial infarction,
             percutaneous trans luminal coronary revascularization, coronary bypass graft, valvular
             surgery or unstable angina.

          -  Patients with evidence of resting bradycardia (&lt;50 bpm) via palpation.

          -  Patients with a history of heart block greater than First Degree Sino atrial Block.
             Wolff-Parkinson-White Syndrome, Sick Sinus Syndrome, Atrial Fibrillation, Atrial
             Flutter, Congestive Heart Failure, or other manifestations of clinically significant
             cardiac valvular disease.

          -  Patients with hemodynamically significant cardiac valvular disease.

          -  Patients with evidence of significant chronic renal impairment as indicated by a serum
             creatinine of &gt; 2.5mg/dL

          -  Patients with evidence of liver disease as indicated by AST (SGOT) or ALT (SGPT) &gt; 2.5
             times or total bilirubin &gt; 1.5 times, the upper limit of the laboratory normal range.

          -  Patients who demonstrate other laboratory test values deviating from the Normal range
             which are considered to be clinically significant by the investigator.

          -  Patient with a history or presence of gastrointestinal disease which may interfere
             with drug absorption.

          -  Patients with insulin and non-insulin dependent diabetes mellitus not controlled on
             diet, insulin or oral hypoglycemic as defined by a HgA1c &gt;10.

          -  Severe psychological or emotional condition which may interfere with participation in
             the study.

          -  History of or current use of illicit drugs or alcohol abuse.

          -  Participation in a clinical trial and taking any investigation drug within 30 days
             prior to enrolling into the study (Screening Visit).

          -  A physical condition that would limit accurate BP measurement.

          -  Inability to swallow a tablet or capsule.

          -  History of moderate or sever asthma or Chronic obstructive pulmonary disease.

          -  Any other medical condition which, in the Investigator's opinion, may render the
             patient unable to complete the study or which would interfere with optimal
             participation in the study or produce significant risk to the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry A Punzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Punzi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Punzi Medical Center</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>August 16, 2018</last_update_submitted>
  <last_update_submitted_qc>August 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

